Cover image of GRACEcast Lung Cancer Audio
(1)
Health & Fitness
Medicine
Science

GRACEcast Lung Cancer Audio

Updated about 15 hours ago

Health & Fitness
Medicine
Science
Read more

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Read more

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

iTunes Ratings

1 Ratings
Average Ratings
1
0
0
0
0

iTunes Ratings

1 Ratings
Average Ratings
1
0
0
0
0
Cover image of GRACEcast Lung Cancer Audio

GRACEcast Lung Cancer Audio

Updated about 15 hours ago

Read more

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Rank #1: Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (audio)

Podcast cover
Read more

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.

May 30 2013
16 mins
Play

Rank #2: ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)

Podcast cover
Read more

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

Aug 23 2013
9 mins
Play

Rank #3: ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (audio)

Podcast cover
Read more

Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.

Aug 11 2013
8 mins
Play

Rank #4: ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)

Podcast cover
Read more

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.

Sep 04 2013
5 mins
Play

Rank #5: ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)

Podcast cover
Read more

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.

Aug 23 2013
7 mins
Play

Rank #6: ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio)

Podcast cover
Read more

Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.

Aug 15 2013
12 mins
Play

Rank #7: ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (audio)

Podcast cover
Read more

Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.

Aug 07 2013
7 mins
Play

Rank #8: ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)

Podcast cover
Read more

Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.

Aug 16 2013
6 mins
Play

Rank #9: ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)

Podcast cover
Read more

Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

Aug 13 2013
8 mins
Play

Rank #10: ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio)

Podcast cover
Read more

Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.

Aug 14 2013
6 mins
Play

Rank #11: Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)

Podcast cover
Read more

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

May 17 2013
11 mins
Play

Rank #12: Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (audio)

Podcast cover
Read more

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.

May 20 2013
19 mins
Play

Rank #13: Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)

Podcast cover
Read more

Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.

Jun 09 2013
21 mins
Play

Rank #14: Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (audio)

Podcast cover
Read more

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).

May 13 2013
12 mins
Play

Rank #15: Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)

Podcast cover
Read more

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

Apr 07 2013
3 mins
Play

Rank #16: Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)

Podcast cover
Read more

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Mar 29 2013
5 mins
Play

Rank #17: Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)

Podcast cover
Read more

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Mar 23 2013
10 mins
Play

Rank #18: Dr. Harpole on Lung Surgery: Advances in Lung Cancer Staging (audio)

Podcast cover
Read more

Dr. David Harpole of Duke University reviews advances in lung cancer surgery, focusing in this first part on the evolution of techniques to improve staging of lung cancer.

Feb 11 2013
11 mins
Play

Rank #19: ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)

Podcast cover
Read more

Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.

Sep 12 2012
5 mins
Play

Rank #20: ASCO 2012 LC Highlights: Dr. Joel Neal on the MEK Inhibitor Selumetinib in KRAS Mutation-Positive NSCLC (audio)

Podcast cover
Read more

Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).

Sep 11 2012
5 mins
Play

Similar Podcasts